GlassScriptPhysician profile
Erik Dwight Stickney
NPI 1619937984
$3,147.36
in general payments reported to CMS, 2019-2025
25 companies · $307 in 2025
The $307 reported for 2025 was more than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,187 · 2020: $117 · 2021: $279 · 2022: $117 · 2023: $471 · 2024: $670 · 2025: $307.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,448.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,447.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Elekta, INC. | $1,342.56 | 2019-2021 | |
| Reflexion Medical, INC. | $403.16 | 2023 | Reflexion Medical Radiotherapy System |
| Siemens Medical Solutions USA, INC. | $354.50 | 2024 | Varian Ethos Treatment Planning |
| Viewray Technologies INC | $123.93 | 2019 | |
| Novartis Pharmaceuticals Corporation | $115.76 | 2024-2025 | |
| Daiichi Sankyo INC. | $114.41 | 2022-2025 | Enhertu, Injectafer |
| Janssen Biotech, INC. | $110.62 | 2021-2025 | Talvey, Tecvayli, Carvykti |
| Astrazeneca Pharmaceuticals LP | $89.51 | 2022-2025 | Enhertu |
| Blue Earth Diagnostics | $57.54 | 2021-2023 | |
| Eisai INC. | $49.60 | 2024 | |
| Incyte Corporation | $39.02 | 2025 | Jakafi, Monjuvi, Zynyz |
| Blueprint Medicines Corporation | $38.25 | 2024-2025 | Ayvakit |
| Exelixis INC. | $34.29 | 2024 | Cabometyx |
| Pfizer INC. | $32.37 | 2024 | |
| Genentech USA, INC. | $30.84 | 2025 | Itovebi |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Progenics Pharmaceuticals, INC. | $25.73 | 2023 | Pylarify |
| Karyopharm Therapeutics INC. | $24.87 | 2025 | Xpovio |
| Stryker Corporation | $23.42 | 2025 | Clottriever Bold Catheter |
| Novocure INC. | $21.85 | 2024 | Optune |
| Boston Scientific Corporation | $20.53 | 2023 | Spaceoar Vue System - 10ml |
| Astellas Pharma US INC | $20.20 | 2025 | Padcev |
| Merck Sharp & Dohme LLC | $19.73 | 2024 | Keytruda |
| Seagen INC. | $19.09 | 2022 | |
| Sobi, INC | $17.84 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.74 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erik Stickney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.